2. Theuretzbacher U., Paul M. Revival of old antibiotics: structuring the re-development process to optimize usage. Clin Microbiol Infect. 2015; 21(10):878–880.

3. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014; 28(1):1–13.

4. Kozlov R.S. Selection of resistant microorganisms when using antimicrobial drugs: the concept of «parallel damage». Clinical Microbiology and Antimicrobial Chemotherapy. 2010; 12(4):284–294. Russian (Козлов Р.С. Селекция резистентных микроорганизмов при использовании антимикробных препаратов: концепция «параллельного ущерба». Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(4):284–294).

5. Anger J., Lee U., Ackerman A.L., et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol 2019; 202:282–289.

6. Hendlin D., Stapley E.O., Jackson M. et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science. 1969; 166(3901):122–123.

7. Naber K.G., Bergman B., Bishop M.C. et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol. 2001; 40(5):576–588.

8. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona Spain 2010. ISBN 978-90-79754-70-0.

9. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Eidelstein M.V., Perepanova T.S., Kozlov R.S., research group «DARMIS-2018». Antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: results of the multicenter study «DARMIS-2018». Clinical Microbiology and Antimicrobial Chemotherapy 2019; 21(2):134–146. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С., исследовательская группа «ДАРМИС-2018». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия 2019; 21(2):134–146).

10. Cai T., Palagin I., Brunelli R. et al. Office-based approach to urinary tract infections in 50 000 patients: results from the REWIND study. Int J Antimicrob Agents. 2020; 56(1):105966.

11. Palagin I.S., Sukhorukova M.V., Dekhnich A.V., Eidelstein M.V., Perepanova T.S., Kozlov R.S., research group «DARMIS-2018». Antibiotic resistance of pathogens of community-acquired urinary tract infections in Russia: results of the multicenter study «DARMIS-2018». Clinical Microbiology and Antimicrobial Chemotherapy 2019; 21(2):134–146. Russian (Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Перепанова Т.С., Козлов Р.С., исследовательская группа «ДАРМИС-2018». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия 2019; 21(2):134–146).

12. Johansen T.E.B., Livermore D.M., Cai T., Tutone M. SURF (SUsceptibility and Resistance of uropathogens to Fosfomycin in comparison with other antimicrobial agents): an international microbiological surveillance study. Poster presented at the 40th Congress of the Societe Internationale d’Urologie, 2020 Oct 10–11, virtual.

13. Kahan F.M., Kahan J.S., Cassidy P.J., Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974; 235(0):364–386.

14. Marquardt J.L., Brown E.D., Lane W.S. et al. Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvoyl transferase by the antibiotic fosfomycin. Biochemistry. 1994; 33(35):10646–10651.

15. Silver L.L. Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med. 2017; 7(2):a025262.

16. Castañeda-García A., Blázquez J., Rodríguez-Rojas A. Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel). 2013 16;2(2):217–236.

17. Bergan T., Mastropaolo G., Di Mario F., Naccarato R. In: Neu H., Williams JD, editors. New trends in urinary tract infections. Basel Karger, 1988:157–166.

18. Zhanel G.G., Zhanel M.A., Karlowsky J.A. Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli. Can J Infect Dis Med Microbiol. 2018; 2018:1404813.

19. Pourbaix A., Guérin F., Burdet C. et al. Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis. Antimicrob Agents Chemother. 2019; 63(8):e00903–19.

20. Falagas M.E., Giannopoulou K.P., Kokolakis G.N., Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008; 46(7):1069–1077.

21. de Cueto M., López L., Hernández J.R. et al. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50:368–370.

22. Allerberger F., Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 43:211–227.

23. Endimiani A., Patel G., Hujer K.M. et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010; 54:526–529.

24. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum betalactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43–50.

25. Rodríguez-Baño J., Alcalá J.C., Cisneros J.M. et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168:1897–1902.

26. Coronado-Alvarez M.N., Parra D., Parra-Ruiz J. Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci. Enferm Infecc Microbiol Clin. 2019; 37(1):4–10.

27. Monzón M., Oteiza C., Leiva J. et al. Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics. Diagn Microbiol Infect Dis. 2002;44:319–324.

28. Rodríguez-Martínez J.M., Ballesta S., Pascual A. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms. Int J Antimicrob Agents 2007;30:366–368.

29. Chai D., Liu X., Wang R., Bai Y., Cai Y. Efficacy of Linezolid and Fosfomycin in Catheter-Related Biofilm Infection Caused by Methicillin-Resistant Staphylococcus aureus. Biomed Res Int. 2016;:6413982.

30. Del Rio A., Gasch O., Moreno A., et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis. 2014;59:1105–1112.

31. Miró J.M., Entenza J.M., Del Río A. et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillinresistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 2012;56(8):4511–4515.

32. Shaw E., Miró J.M., Puig-Asensio M. et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial. BMJ Open. 2015;5(3): e006723.

33. Gudiol F., Aguado J.M., Almirante B. et al. Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015;33(9):625.e1-625.e23.

34. Gutiérrez-Gutiérrez B., Salamanca E., de Cueto M., et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;17:726–734.

35. Pontikis K., Karaiskos I., Bastani S. et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Intern J Antimicrob Agents 2014; .43: .52–59.

36. Papst L., Beović B., Pulcini C. et al.; ESGAP, ESGBIS, ESGIE and the CRGNB treatment survey study group. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070–1076.

37. Bassetti M., Peghin M., Pecori D. The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis 2016, 29:583–594. Silva J.T., Fernández-Ruiz M., Aguado J.M. Multidrug-resistant Gramnegative infection in solid organ transplant recipients: implications for outcome and treatment. Curr Opin Infect Dis. 2018;31(6):499505.

38. Kaye K.S., Rice L.B., Dane A. et al. Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis 2019;69(12):2045–2056.

39. The White House. National Action Plan for Combating Antibiotic-Resistant Bacteria. 2015. Available at: https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria. pdf. Accessed 11 June 2019.

40. Gardiner B.J., Stewardson A.J., Abbott I.J., Peleg A.Y. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Aust Prescr 2019; 42:14–19.

41. Moroni M.. Monuril in lower uncomplicated urinary tract infections in adults. Eur Urol 1987;13(1):101–104.

42. Pullukcu H., Tasbakan M., Sipahi O.R., Yamazhan T., Aydemir S., and Ulusoy S.. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. International Journal of Antimicrobial Agents 2007;29(1):62–65.

43. Senol S., Tasbakan M., Pullukcu H. et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-Producing Escherichia coli-related complicated lower urinary tract infection. Journal of Chemotherapy 2010; 22 (5):355–357.

44. Neuner E.A., Sekeres J., Hall G.S., and van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrobial Agents and Chemotherapy 2012; 56(11):5744–5748.

45. Qiao L.D., Zheng B., Chen S. et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 2013; 3(12):e004157.

46. Matthews L.K., Barrett, Warren S. et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective P. C. cohort study. BMC Infectious Diseases 2016;16(1):556.

47. Veve M.P., Wagner J.L., Kenney R.M., Grunwald J.L., Davis S.L. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. International Journal of Antimicrobial Agents 2016; 48(1):56–60.

48. Jacobson S., Junco Noa L., Ahmed S., Wallace M.R. Efficacy and safety of oral fosfomycin for urinary tract infections in hospitalized patients. Antimicrobial Agents and Chemotherapy 2016;60(3):1952.

49. Giancola S.E., Mahoney M.V., Hogan M.D., Raux B.R., McCoy C., Hirsch E.B. Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: patient characteristics and outcomes. Chemotherapy 2017;62(2):100–104.

50. Cai T., Cocci A., Verze P. et al. The use of oral fosfomycintrometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic? Journal of Chemotherapy 2018;30(5):290–295.

51. Derington C.G., Benavides N., Delate T., Fish D.N. Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting. Open Forum Infect Dis. 2020 Jan 29;7(2):ofaa034.

52. Cystitis in women. Clinical recommendations of the Ministry of Health of the Russian Federation, 2021. Russian (Цистит у женщин. Клинические рекомендации Министерства здравоохранения Российской Федерации, 2021). Available at: https://cr.minzdrav.gov.ru/recomend/14_2. Accessed 16 December 2021.

53. Zhanel G.G., Zhanel M.A., Karlowsky J.A. Oral fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by multidrug-resistant Escherichia coli. Can J Infect Dis Med Microbiol 2018;2018:1404813.

54. Karaiskos I., Giamarellou H. Multidrug-resistant and extensively drug resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014; 15:1351–1370.

55. Gardiner B.J., Mahony A.A., Ellis A.G. et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis 2014; 58: e101–105.

56. Karaiskos I., Galani L., Sakka V. et al. Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 2019;74(5):1430–1437.